Skip to main content

Neumora Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Neumora. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neumora, are expected to be approximately $250 million. In addition, Neumora has granted the underwriters a 30-day option to purchase up to 2,206,500 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on September 15, 2023 under the ticker symbol “NMRA.” The initial public offering is expected to close on September 19, 2023, subject to the satisfaction of customary closing conditions.

J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets, and William Blair are acting as joint book-running managers for the offering.

A registration statement relating to the shares of common stock being sold in the initial public offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on September 14, 2023. A copy of the registration statement can be accessed through the SEC’s website at The offering is being made only by means of a prospectus. When available, a copy of the final prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at; BofA Securities, NC1-0220-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina, 28255-0001, or by email at; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at; RBC Capital Markets LLC, Attention: Equity Syndicate Department, 200 Vesey Street, 8th Floor, New York, New York 10281, by telephone at (877) 822-4089, or by email at; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Neumora’s therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora’s work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. Neumora has operations in the Greater Boston Area and South San Francisco.

Neumora Contact

Helen Rubinstein
Investor Relations & Communications
Mobile: 315-382-3979

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.